Abstract
Numerous proteins responsible for cell proliferation and differentiation exist either as hetero or homodimers or become activated through dimerization as a key step in their respective signaling cascade. Many of these proteins have been identified as major components in oncogenic signaling pathways and have become popular targets for the development of anti-tumor agents. For this reason, bivalent anti-cancer drugs that could potentially interact with each monomer of a dimeric protein target have been developed. This review provides a brief background on prevalent dimeric drug targets within the anti-cancer field and focuses mainly on dimeric natural product and synthetic cancer chemotherapeutics.
Keywords: Anti-cancer, dimer, natural product dimers, synthetic dimers, bisintercalators
Anti-Cancer Agents in Medicinal Chemistry
Title: Dimeric Approaches to Anti-Cancer Chemotherapeutics
Volume: 8 Issue: 7
Author(s): M. K. Hadden and B. S.J. Blagg
Affiliation:
Keywords: Anti-cancer, dimer, natural product dimers, synthetic dimers, bisintercalators
Abstract: Numerous proteins responsible for cell proliferation and differentiation exist either as hetero or homodimers or become activated through dimerization as a key step in their respective signaling cascade. Many of these proteins have been identified as major components in oncogenic signaling pathways and have become popular targets for the development of anti-tumor agents. For this reason, bivalent anti-cancer drugs that could potentially interact with each monomer of a dimeric protein target have been developed. This review provides a brief background on prevalent dimeric drug targets within the anti-cancer field and focuses mainly on dimeric natural product and synthetic cancer chemotherapeutics.
Export Options
About this article
Cite this article as:
Hadden K. M. and Blagg S.J. B., Dimeric Approaches to Anti-Cancer Chemotherapeutics, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914743
DOI https://dx.doi.org/10.2174/187152008785914743 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Disseminated TB in an Immunocompetent Patient: A Case Report
Infectious Disorders - Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets A Review on Rheumatoid Arthritis Interventions and Current Developments
Current Drug Targets MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Antiproliferative and Pro-Apoptotic Effects of Thiazolo[3,2–b][1,2,4]triazoles in Breast and Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Cellular and Physiological Effects of Ganoderma lucidum (Reishi)
Mini-Reviews in Medicinal Chemistry The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Computational Investigation of Zerumbone as an Inhibitor of TNF-alpha Using Molecular Dynamics and Molecular Docking Methods
Letters in Drug Design & Discovery Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews